kidney cancer News
-
Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed Murine Renal Cancer and Metastasis
Alpha-1 Biologics, a biotherapeutics company developing innovative treatments for cancers and immune deficiencies, today announced that positive data was published in frontiers in Oncology demonstrating Alphataxin, a small molecule that elevates circulating and tumor-infiltrating CD4+ T cells, suppressed kidney cancer and suppressed metastasis in mice. Orally available Alphataxin, is the first ...
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
-
City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab ...
By Osel Inc.
-
FDA Approves BAVENCIO (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line treatment of patients with advanced renal cell carcinoma (RCC) Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended progression-free survival by 5.4 months for patients with advanced RCC compared with sunitinib Combination approved based on ...
By Siemens AG
-
Solvents and Exposure Concerns Discussed in New Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses solvents and potential occupational and residential exposures to these chemicals. “One of the most common ways people are exposed to solvents is through inhalation, but solvents can also be absorbed through the skin or ingested,” said ...
-
Emory University research links functional thyroid disease, PFOA exposure
Excessive perfluorooctanoic acid (PFOA) exposure appears to be associated with thyroid disease, according to new research. A study by Kyle Steenland, environmental health professor at Emory University's Rollins School of Public Health, tracking the disease within a large high-exposure group concludes that the chemical “was associated with incident functional thyroid disease.” ...
-
Call for applications: the Amgen award for science teaching excellence
Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen ...
-
MedBiome licenses the MetaLab metaproteomic software
MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, ...
-
cure bioscience and immunotech Biopharm Ltd. Announce license agreement for novel HERV-E T cell receptor therapy
Immunotech Biopharm Ltd will have rights to develop and commercialize 800TCR, a HERV-E targeting T cell receptor (TCR) therapy for the treatment of kidney cancer, in China T- Cure Bioscience to receive an upfront payment and future development milestones and royalties Sherman Oaks, CA – January 20, 2021 – T-Cure Bioscience, Inc., a privately held clinical-stage immuno-oncology ...
-
TVAX Biomedical Names Wayne Carter as President and CEO
TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for the treatment of cancer, today announced the decision of the board to hire Dr. Wayne Carter as president and chief executive officer effective immediately. TVAX Biomedical is planning phase 2 clinical studies for glioblastoma multiforme, an orphan disease for which there is no effective ...
-
MedBiome licenses the RapidAIM technology from the University of Ottawa
MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the ...
-
NCI and rutgers university open phase 1 clinical trials of t cell receptor therapy targeting KK-LC-1for multiple solid tumors
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) expressing malignancies, ...
-
Icecure medical ltd. Closes $17 million underwritten public offering and partial exercise of over-allotment option
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the “Company” or “IceCure”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the closing of its underwritten public offering of 3,892,152 shares of the Company’s ordinary shares, ...
-
T-cure bioscience enters into agreement with rutgers to conduct clinical research of novel t cell receptor therapy for treatment of variety of cancers
Sherman Oaks, CA – March 17, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based product candidate for ...
-
Biosceptre Wins Funding from the UK Government-Backed, SMART Award to Develop Novel Cancer Diagnostic and Therapeutic Targets
Cambridge, UK, 8th February 2016 – Biosceptre, a biopharmaceutical company developing innovative diagnostic and therapeutic approaches to cancer, today announced that the UK government-backed Innovate UK SMART award scheme, has awarded the company £100,000 to support pre-clinical development of diagnostic approaches and antibodies to target Kidney and Lung cancers. This project will ...
-
INCOGEN Presents at BioPharma Asia and PepCon
INCOGEN will present two invited talks at the BioPharma Asia conference in Singapore and the PepCon conference in Beijing, China. The presentations will describe recent progress of our NCI-funded renal cancer project conducted in collaboration with Mayo Clinic, Eastern Virginia Medical School, and Johns Hopkins University. ...
-
Amgen Foundation recognizes outstanding staff volunteers and contributes $55,000 to their favorite local nonprofits
Amgen today announced the 11 recipients of the Amgen Excellence in Volunteering Awards. Launched this year by the Amgen Foundation, the Awards recognize staff in the United States (U.S.) and Puerto Rico who are making a difference in the communities where the company has a presence. The Amgen Foundation will award $5,000 to each nonprofit organization featured in the winning staff members' ...
-
T-Cure bioscience announces U.S. FDA clearance of investigator – initiated clinical trial for KK-LC-1 TCR-T against multiple solid tumors
LOS ANGELES, CA, September 15, 2021 T–Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor therapy (TCR–T) products for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I clinical study evaluating a TCR–based ...
-
Icecure Medical Receives Notice of Intention to Grant a European Patent Covering its Cryogenic Pump
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it received notification from the European Patent Office (the “EPO”) of an intention to grant a patent ...
-
T-cure bioscience, inc. And atlas antibodies ab enter a collaboration agreement for the development, manufacture, and supply of CT83 (KK-LC-1) monoclonal antibodies
LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, announced today a collaborative agreement for the development, manufacture, and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you